» Articles » PMID: 30657336

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018

Abstract

Objective: To provide a snapshot of the profile of adults and youth with type 1 diabetes (T1D) in the United States and assessment of longitudinal changes in T1D management and clinical outcomes in the T1D Exchange registry.

Research Design And Methods: Data on diabetes management and outcomes from 22,697 registry participants (age 1-93 years) were collected between 2016 and 2018 and compared with data collected in 2010-2012 for 25,529 registry participants.

Results: Mean HbA1c in 2016-2018 increased from 65 mmol/mol at the age of 5 years to 78 mmol/mol between ages 15 and 18, with a decrease to 64 mmol/mol by age 28 and 58-63 mmol/mol beyond age 30. The American Diabetes Association (ADA) HbA1c goal of <58 mmol/mol for youth was achieved by only 17% and the goal of <53 mmol/mol for adults by only 21%. Mean HbA1c levels changed little between 2010-2012 and 2016-2018, except in adolescents who had a higher mean HbA1c in 2016-2018. Insulin pump use increased from 57% in 2010-2012 to 63% in 2016-2018. Continuous glucose monitoring (CGM) increased from 7% in 2010-2012 to 30% in 2016-2018, rising >10-fold in children <12 years old. HbA1c levels were lower in CGM users than nonusers. Severe hypoglycemia was most frequent in participants ≥50 years old and diabetic ketoacidosis was most common in adolescents and young adults. Racial differences were evident in use of pumps and CGM and HbA1c levels.

Conclusions: Data from the T1D Exchange registry demonstrate that only a minority of adults and youth with T1D in the United States achieve ADA goals for HbA1c.

Citing Articles

Adipose stromal cells increase insulin sensitivity and decrease liver gluconeogenesis in a mouse model of type 1 diabetes mellitus.

Lai H, Lee Y, Chen P, Tang C, Chen L Stem Cell Res Ther. 2025; 16(1):133.

PMID: 40069851 PMC: 11899698. DOI: 10.1186/s13287-025-04225-5.


The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.

Seetharaman S, Cengiz E J Diabetes Sci Technol. 2025; 19(2):311-320.

PMID: 40022528 PMC: 11686489. DOI: 10.1177/19322968241309896.


Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.

Infante M, Silvestri F, Padilla N, Pacifici F, Pastore D, Pinheiro M J Clin Med. 2025; 14(4).

PMID: 40004833 PMC: 11856673. DOI: 10.3390/jcm14041303.


From Guidelines to Lifelines-An Ethnographic Study of How Diabetes Management Is Emplotted During Clinical Encounters with Young Adults with Type 1 Diabetes.

Schonning S, Wahlberg A, Hommel E, Grabowski D Healthcare (Basel). 2025; 13(4).

PMID: 39997249 PMC: 11855098. DOI: 10.3390/healthcare13040374.


Breath Acetone Correlates with Capillary β-hydroxybutyrate in Type 1 Diabetes.

Jones K, Petersen M, Markov A, Salam M, Krutilova P, McKee A medRxiv. 2025; .

PMID: 39974120 PMC: 11838673. DOI: 10.1101/2025.01.30.25321320.


References
1.
Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U . Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA. 2017; 318(14):1358-1366. PMC: 5818842. DOI: 10.1001/jama.2017.13994. View

2.
Maahs D, Hermann J, DuBose S, Miller K, Heidtmann B, DiMeglio L . Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia. 2014; 57(8):1578-85. DOI: 10.1007/s00125-014-3272-2. View

3.
Miller K, Foster N, Beck R, Bergenstal R, DuBose S, DiMeglio L . Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015; 38(6):971-8. DOI: 10.2337/dc15-0078. View

4.
Beck R, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S . Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017; 317(4):371-378. DOI: 10.1001/jama.2016.19975. View

5.
Haynes A, Hermann J, Miller K, Hofer S, Jones T, Beck R . Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatr Diabetes. 2016; 18(7):643-650. PMC: 7162500. DOI: 10.1111/pedi.12477. View